HLB Life Science Co., Ltd. 067630.KQ Stock
HLB Life Science Co., Ltd. Price Chart
HLB Life Science Co., Ltd. 067630.KQ Financial and Trading Overview
HLB Life Science Co., Ltd. stock price | 16530 KRW |
Previous Close | 10320 KRW |
Open | 10320 KRW |
Bid | 10270 KRW x 0 |
Ask | 10280 KRW x 0 |
Day's Range | 10210 - 10460 KRW |
52 Week Range | 9698.6 - 17257.8 KRW |
Volume | 609.69K KRW |
Avg. Volume | 871.67K KRW |
Market Cap | 480.6B KRW |
Beta (5Y Monthly) | 0.462495 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 KRW |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
067630.KQ Valuation Measures
Enterprise Value | 1.14T KRW |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 5.484594 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 12.978 |
Enterprise Value/EBITDA | -61.918 |
Trading Information
HLB Life Science Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.462495 |
52-Week Change | -7.62% |
S&P500 52-Week Change | 20.43% |
52 Week High | 17257.8 KRW |
52 Week Low | 9698.6 KRW |
50-Day Moving Average | 11071 KRW |
200-Day Moving Average | 11342.09 KRW |
067630.KQ Share Statistics
Avg. Volume (3 month) | 871.67K KRW |
Avg. Daily Volume (10-Days) | 677.61K KRW |
Shares Outstanding | 46.84M |
Float | 81.97M |
Short Ratio | N/A |
% Held by Insiders | 20.36% |
% Held by Institutions | 7.54% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | N/A |
Trailing Annual Dividend Yield | N/A |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor | 1.051698:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2021 |
Most Recent Quarter (mrq) | September 30, 2022 |
Next Fiscal Year End | December 31, 2022 |
Profitability
Profit Margin | -64.70% |
Operating Margin (ttm) | -23.99% |
Gross Margin | -6.84% |
EBITDA Margin | -20.95% |
Management Effectiveness
Return on Assets (ttm) | -3.21% |
Return on Equity (ttm) | -18.98% |
Income Statement
Revenue (ttm) | 87.63B KRW |
Revenue Per Share (ttm) | 867.56 KRW |
Quarterly Revenue Growth (yoy) | 193.50% |
Gross Profit (ttm) | -5660739670 KRW |
EBITDA | -18367088640 KRW |
Net Income Avi to Common (ttm) | -56699850752 KRW |
Diluted EPS (ttm) | N/A |
Quarterly Earnings Growth (yoy) | -75.79% |
Balance Sheet
Total Cash (mrq) | 191.93B KRW |
Total Cash Per Share (mrq) | 1888 KRW |
Total Debt (mrq) | 144.15B KRW |
Total Debt/Equity (mrq) | 48.68 KRW |
Current Ratio (mrq) | 5.639 |
Book Value Per Share (mrq) | N/A |
Cash Flow Statement
Operating Cash Flow (ttm) | -23048550400 KRW |
Levered Free Cash Flow (ttm) | -19987632128 KRW |
Profile of HLB Life Science Co., Ltd.
Country | South Korea |
State | N/A |
City | Hwaseong-si |
Address | 51-9, Dongtancheomdansaneop 1-ro |
ZIP | N/A |
Phone | 82 2 2627 6700 |
Website | https://www.hlb-ls.com |
Industry | |
Sector(s) | |
Full Time Employees | 26 |
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/ß-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood. Further, it is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses. The company also undertakes energy efficiency projects; and builds heating/heating system improvement projects. The company was formerly known as Energy Solutions Co., Ltd. and changed its name to HLB Life Science Co.,Ltd. in December 2015. HLB Life Science Co.,Ltd. was founded in 1998 and is headquartered in Hwaseong, South Korea.
Q&A For HLB Life Science Co., Ltd. Stock
What is a current 067630.KQ stock price?
HLB Life Science Co., Ltd. 067630.KQ stock price today per share is 16530 KRW.
How to purchase HLB Life Science Co., Ltd. stock?
You can buy 067630.KQ shares on the KOSDAQ exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for HLB Life Science Co., Ltd.?
The stock symbol or ticker of HLB Life Science Co., Ltd. is 067630.KQ.
How many shares does HLB Life Science Co., Ltd. have in circulation?
The max supply of HLB Life Science Co., Ltd. shares is 101.78M.
What is HLB Life Science Co., Ltd. Price to Earnings Ratio (PE Ratio)?
HLB Life Science Co., Ltd. PE Ratio is now.
What was HLB Life Science Co., Ltd. earnings per share over the trailing 12 months (TTM)?
HLB Life Science Co., Ltd. EPS is 0 KRW over the trailing 12 months.